Lista de obras -

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

artículo científico publicado en 2016

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

artículo científico publicado en 2020

Author reply

artículo científico publicado en 2019

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

artículo científico publicado en 2016

Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales.

artículo científico publicado en 2008

Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis

artículo científico publicado en 2015

Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply

artículo científico publicado en 2019

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

artículo científico publicado en 2016

Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease

artículo científico publicado en 2015

Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma.

artículo científico publicado en 2013

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

scientific article published on 27 February 2019

Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice

artículo científico publicado en 2016

Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma

scientific article published on 01 September 2019

Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma

scientific article published on 01 April 2019

Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration

artículo científico publicado en 1999

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

artículo científico publicado en 2016

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

scientific article published on 01 April 2020

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

artículo científico publicado en 2018

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

artículo científico publicado en 2016

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

scientific article published on 01 June 2018

Invasive pneumococcal disease in central Australia.

artículo científico publicado en 1995

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

artículo científico publicado en 2017

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

artículo científico publicado en 2019

Management of patients with follicular lymphoma treated first line with obinutuzumab

scientific article published on 01 May 2019

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

artículo científico publicado en 2016

PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study

artículo científico

Pharmacokinetics of melphalan in myeloma patients undergoing an autograft

artículo científico publicado en 2007

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

artículo científico publicado en 2019

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

artículo científico publicado en 2010

Positron emission tomography-computed tomography in follicular lymphoma: "one fit for all"?

artículo científico publicado en 2015

Primary objective of Concord Haematology Clinical Research Unit is to contribute independently to quality clinical research

artículo científico publicado en 2020

Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.

artículo científico publicado en 2018

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies

artículo científico publicado en 2014

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

article

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

artículo científico publicado en 2019

Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement.

artículo científico publicado en 2013

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al

artículo científico publicado en 2015

Reply to G. Keramida et al.

artículo científico publicado en 2015

Reply to H.J.A. Adams et al and E. Laffon et al

scientific article published on 28 December 2016

Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting

artículo científico publicado en 2019

Rising cost of anticancer drugs in Australia.

artículo científico publicado en 2014

Role of early PET in the management of diffuse large B-cell lymphoma.

artículo científico publicado en 2010

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

artículo científico publicado en 2014

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström Macroglobulinemia.

artículo científico publicado en 2018

Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function

artículo científico publicado en 2007

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

artículo científico publicado en 2014

Time to publish: challenging the performance of cooperative group lymphoma trials

artículo científico publicado en 2016

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

artículo científico publicado en 2017

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

artículo científico publicado en 2017

Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience.

artículo científico publicado en 2012

Lista de obras de

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Author reply

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales.

Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis

Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease

Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma.

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice

Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma

Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma

Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Invasive pneumococcal disease in central Australia.

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Management of patients with follicular lymphoma treated first line with obinutuzumab

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study

Pharmacokinetics of melphalan in myeloma patients undergoing an autograft

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Positron emission tomography-computed tomography in follicular lymphoma: "one fit for all"?

Primary objective of Concord Haematology Clinical Research Unit is to contribute independently to quality clinical research

Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al

Reply to G. Keramida et al.

Reply to H.J.A. Adams et al and E. Laffon et al

Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting

Rising cost of anticancer drugs in Australia.

Role of early PET in the management of diffuse large B-cell lymphoma.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström Macroglobulinemia.

Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Time to publish: challenging the performance of cooperative group lymphoma trials

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience.